John Niblack, PhD, to exec VP-R&D upon the retirement of Barry Bloom, PhD, Sept. 1. George Milne, PhD, will succeed Niblack as president of Pfizer Central Research, and Craig Saxton, MD, will become exec VP of Central Research. Milne and Saxton have both been elected corporate VPs. Bloom joined Pfizer in 1952 and was named Central Research president in 1971 and corporate exec VP in 1992. Pfizer Chairman William Steere praised Bloom's career at Pfizer, saying he "elevated the status of Pfizer research and clearly focused its efforts so that today it stands as the envy of the industry".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth